A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer

Yam, Clinton; Rauch, Gaiane M.; Rahman, Tahminur; Karuturi, Meghan Sri; Ravenberg, Elizabeth; White, Jason B.; Clayborn, Alyson R.; McCarthy, Pamela; Abouharb, Sausan; Litton, Jennifer K.; Ramirez, David Luis; Saleem, Sadia; Stec, James; Symmans, W. Fraser; Huo, Lei; Damodaran, Senthil; Sun, Ryan; Moulder, Stacy L.

doi:10.1007/s10637-020-00995-2

Cited by 22 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from these combinations showed a good tolerability profile along with promising activity, thus justifying a subsequent development in larger trials. Of note, a phase II study investigating mirvetuximab soravtansine in FRα-expressing TNBC was closed prematurely because of a low rate of FRα positivity in the screened population and lack of response in two patients treated [ 105 ]. Other studies enrolling patients with endometrial cancers are underway (Table 2 ).…”

Section: Promising New Targets Under Investigationmentioning

confidence: 99%

Antibody–drug conjugates in solid tumors: a look into novel targets

2021

View full text Add to dashboard Cite

Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. They are commonly described as the “Trojan Horses” of therapeutic armamentarium, because of their capability of directly conveying cytotoxic drug (payloads) into the tumor space, thus transforming chemotherapy into a targeted agent. Three novel ADCs have been recently approved, i.e., trastuzumab deruxtecan, sacituzumab govitecan and enfortumab vedotin, respectively, targeting HER2, Trop2 and Nectin4. Thanks to progressive advances in engineering technologies these drugs rely on, the spectrum of diseases sensitive to these drugs as well as their indications are in continuous expansion. Several novel ADCs are under evaluation, exploring new potential targets along with innovative payloads. This review aims at providing a summary of the technology behind these compounds and at presenting the latest ADCs approved in solid tumors, as well as at describing novel targets for ADCs under investigation and new strategies to optimize their efficacy in solid tumors.

show abstract

Section: Promising New Targets Under Investigationmentioning

confidence: 99%

Antibody–drug conjugates in solid tumors: a look into novel targets

2021

View full text Add to dashboard Cite

show abstract

“…Mirvetuximab soravtansine was evaluated in a lead-in cohort to establish its activity in patients with metastatic TNBC [171]. A phase II study of 25 was conducted in TNBC; however, this study was terminated early due to the low rate of FRα positivity in the screened patient population and the lack of disease response in the two patients treated [172].…”

Section: Mirvetuximab Soravtansine (25)mentioning

confidence: 99%

Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment

Masci,

Naro,

Puxeddu

et al. 2023

Molecules

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is one of the most heterogeneous and aggressive breast cancer subtypes with a high risk of death on recurrence. To date, TNBC is very difficult to treat due to the lack of an effective targeted therapy. However, recent advances in the molecular characterization of TNBC are encouraging the development of novel drugs and therapeutic combinations for its therapeutic management. In the present review, we will provide an overview of the currently available standard therapies and new emerging therapeutic strategies against TNBC, highlighting the promises that newly developed small molecules, repositioned drugs, and combination therapies have of improving treatment efficacy against these tumors.

show abstract

“…Mirvetuximab soravtansine is denoted as a novel ADC that has posed potential efficacy for targeting FRα-positive solid tumors (O'Malley et al, 2020). Mirvetuximab soravtansine was investigated in a prospective phase II trial for the benefit of metastatic TNBC (Yam et al, 2021). The study was terminated early due to a low rate of FRα positivity in the selected patient population and no patients had a partial or complete response.…”

Section: Antibody-drug Conjugatesmentioning

confidence: 99%

Current landscape of personalized clinical treatments for triple-negative breast cancer

et al. 2022

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer (BC) with vicious behaviors. TNBC is usually associated with relatively poor clinical outcomes, earlier recurrence, and high propensity for visceral metastases than other BC types. TNBC has been increasingly recognized to constitute a very molecular heterogeneous subtype, which may offer additional therapeutic opportunities due to newly discovered cancer-causing drivers and targets. At present, there are multiple novel targeted therapeutic drugs in preclinical researches, clinical trial designs, and clinical practices, such as platinum drugs, poly ADP-ribose polymerase (PARP) inhibitors, immunocheckpoint inhibitors, androgen receptor inhibitors as well as PI3K/AKT/mTOR targeted inhibitors. These personalized, single, or combinational therapies based on molecular heterogeneity are currently showing positive results. The scope of this review is to highlight the latest knowledge about these potential TNBC therapeutic drugs, which will provide comprehensive insights into the personalized therapeutic strategies and options for combating TNBC.

show abstract

A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer

Cited by 22 publications

References 27 publications

Antibody–drug conjugates in solid tumors: a look into novel targets

Antibody–drug conjugates in solid tumors: a look into novel targets

Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment

Current landscape of personalized clinical treatments for triple-negative breast cancer

Contact Info

Product

Resources

About